Webb1 apr. 2024 · PIONEER-HF is a prospective, multicenter, double-blind, randomized controlled trial designed to assess the safety, tolerability, and efficacy of in-hospital … Webb3 feb. 2024 · Patients who are hospitalized for acute decompensated heart failure (ADHF) are at high risk for poor outcomes, including recurrent hospitalizations and death. 1 …
The New England Journal of Medicine
Webb30 aug. 2014 · In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice ... Webb19 feb. 2024 · Heart failure (HF) remains a leading source of morbidity, mortality and economic burden worldwide. 1–4 Despite numerous therapeutic breakthroughs provided by landmark clinical trials in stable chronic HF (CHF), there has been little progress over the past two decades in the treatment of acute HF (AHF). 5 Therefore, a new paradigm is … mail tracking for yahoo mail
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in ...
Webb1 apr. 2024 · PIONEER-HF is a prospective, multicenter, randomized, double-blind, active-controlled trial designed to assess the safety, tolerability, and efficacy of sacubitril/valsartan compared with enalapril in patients hospitalized for acute decompensated HF with a reduced EF following stabilization but prior to discharge. Webb21 okt. 2024 · Angiotensin receptor-neprilysin inhibition in patients with de novo acute decompensated heart failure: a prespecified subgroup analysis of the PIONEER-HF trial, European Heart Journal, Volume 40, Issue ... The PIONEER-HF trial was a prospective, multicenter, double-blind, active-controlled, randomized clinical trial which ... Webb16 mars 2024 · Heart Failure and Cardiomyopathies; Invasive Cardiovascular Angiography and Intervention; Noninvasive Imaging; Pericardial Disease; Prevention; Pulmonary … mail traviscountytx gov